Bg pattern

TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose)

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose)

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Trelegy Ellipta 92micrograms/55micrograms/22micrograms inhalation powder, single dose

fluticasone furoate/umeclidinium/vilanterol

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What Trelegy Ellipta is and what it is used for
  2. What you need to know before you use Trelegy Ellipta
  3. How to use Trelegy Ellipta
  4. Possible side effects
  5. Storing Trelegy Ellipta
  6. Contents of the pack and other information

Step-by-step instructions for use

1. What Trelegy Ellipta is and what it is used for

What Trelegy Ellipta is

Trelegy Ellipta contains three active substances called fluticasone furoate, umeclidinium bromide, and vilanterol.

Fluticasone furoate belongs to a group of medicines called corticosteroids, often simply called steroids.

Umeclidinium bromide and vilanterol belong to a group of medicines called bronchodilators.

What Trelegy Ellipta is used for

Trelegy Ellipta is used to treat chronic obstructive pulmonary disease(COPD) in adults. COPD is a long-term disease that gets slowly worse and is characterized by difficulty breathing.

In COPD, the muscles around the airways contract, making it difficult to breathe. This medicine relaxes the muscles in the lungs, reducing swelling and irritation in the smaller airways, and makes it easier for air to get in and out of the lungs. When used regularly, it helps control breathing difficulties and reduces the impact of COPD on daily life.

Trelegy Ellipta should be used every day and not just when you have problems breathing or other COPD symptoms. It should not be used to relieve a sudden attack of shortness of breath or wheezing.If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol). If you do not have a fast-acting "rescue" inhaler, contact your doctor.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Trelegy Ellipta

Do not use Trelegy Ellipta

  • if you are allergic to fluticasone furoate, umeclidinium, vilanterol, or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor before starting to use Trelegy Ellipta

  • if you have asthma(do not use Trelegy Ellipta to treat asthma)
  • if you have heart problemsor high blood pressure
  • if you have liver problems
  • if you have tuberculosis(TB) lung infectionor any other long-standing or untreated infection
  • if you have a glaucomacalled narrow-angle glaucoma
  • if you have an enlarged prostate, difficulty urinating, or a blockage in the bladder
  • if you suffer from epilepsy
  • if you have thyroid problems
  • if you have low potassium levelsin your blood
  • if you have a history of diabetes
  • if you experience blurred visionor other visual disturbances.

Consult your doctorif you think any of the above conditions apply to you.

Urgent breathing difficulties

If you experience chest tightness, coughing, wheezing, or difficulty breathing immediately after using your Trelegy Ellipta inhaler:

stop using this medicineand seek medical help immediately, as you may have a serious condition called paradoxical bronchospasm.

Eye problems during treatment with Trelegy Ellipta

If you experience eye pain or discomfort, blurred vision for a time, halos, colored images, as well as redness of the eyes during treatment with Trelegy Ellipta:

stop using this medicine and seek medical help immediately. These signs may be due to an acute attack of narrow-angle glaucoma.

Lung infection

If you are using this medicine to treat COPD, you may be at a higher risk of developing a lung infection called pneumonia. See section 4 "Possible side effects" for information on the symptoms to look out for while using this medicine.

Consult your doctor as soon as possible if you develop any of these symptoms.

Children and adolescents

This medicine should not be given to children or adolescents under 18 years of age.

Other medicines and Trelegy Ellipta

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. If you are not sure what your medicine contains, consult your doctor or pharmacist.

Some medicines may affect the way this medicine works or make it more likely that you will have side effects. These include:

  • medicines called beta-blockers (such as propranolol), used to treat high blood pressure or other heart diseases
  • ketoconazole or itraconazole, to treat fungal infections
  • clarithromycin or telithromycin, to treat bacterial infections
  • ritonavir or cobicistat to treat HIV
  • medicines that lower the level of potassium in the blood, such as some diuretics or some medicines to treat COPD and asthma (such as methylxanthine or steroids)
  • other long-acting medicines to treat respiratory problems similar to this medicine, for example, tiotropium, indacaterol. Do not use Trelegy Ellipta if you are already using these medicines.

Consult your doctor or pharmacistif you are taking any of these medicines. Your doctor may monitor you closely if you are taking any of these medicines, as they may increase the side effects of Trelegy Ellipta.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. If you are pregnant, do not use this medicine unless your doctor tells you to.

It is not known if the components of Trelegy Ellipta can pass into breast milk. If you are breastfeeding, consult your doctor before using Trelegy Ellipta. If you are breastfeeding, do not use this medicine unless your doctor tells you to.

Driving and using machines

This medicine is unlikely to affect your ability to drive or use machines.

Trelegy Ellipta contains lactose

If your doctor has told you that you have an intolerance to some sugars, consult them before using this medicine.

3. How to use Trelegy Ellipta

Follow the instructions for using this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist again.

The recommended doseis one inhalation every day, at the same time each day. You only need one inhalation a day, as the effect of this medicine lasts for 24 hours.

Do not use more doses than your doctor has told you to.

Use Trelegy Ellipta regularly

It is very important that you use Trelegy Ellipta every day, as your doctor has told you. This will help you not to have symptoms throughout the day and night.

Trelegy Ellipta should notbe used to relieve a sudden attack of shortness of breath or wheezing. If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol).

How to use the inhaler

To get the full instructions, read the "Step-by-step instructions for use" at the end of this leaflet.

Trelegy Ellipta is for inhalation use only.

Trelegy Ellipta is ready to use once the tray is opened.

If your symptoms do not improve

If your COPD symptoms (shortness of breath, wheezing, coughing) do not improve or worsen, or if you are using your fast-acting "rescue" inhaler more often than usual:

contact your doctor as soon as possible.

If you use more Trelegy Ellipta than you should

If you accidentally use more medicine than you should, contact your doctor or pharmacist immediately, as you may need medical attention. If possible, show them the inhaler, packaging, or this leaflet. You may notice that your heart beats faster than normal, feel shaky, have visual disturbances, have a dry mouth, or have a headache.

If you forget to use Trelegy Ellipta

Do not inhale a double dose to make up for a forgotten dose. Inhale the next dose at the usual time. If you have wheezing or shortness of breath, use your fast-acting "rescue" inhaler (such as salbutamol), and seek medical advice.

If you stop using Trelegy Ellipta

Use this medicine for as long as your doctor recommends. Do not stop using it until your doctor tells you to, even if you feel better, as your symptoms may worsen.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions

Allergic reactions to Trelegy Ellipta are rare (may affect up to 1 in 1,000 people).

If you get any of the following symptoms after taking Trelegy Ellipta, stop using itand tell your doctor immediately:

  • skin rash or redness, hives (urticaria)
  • swelling, sometimes of the face or mouth (angioedema)
  • wheezing, coughing, or difficulty breathing
  • a sudden feeling of weakness or dizziness (which may cause fainting or loss of consciousness).

Urgent breathing difficulties

If your breathing or wheezing gets worse immediately after using this medicine, stop using itand seek medical help immediately.

Pneumonia (lung infection)in patients with COPD (common side effect)

If you get any of the following symptoms while using Trelegy Ellipta, consult your doctor. They could be symptoms of a lung infection:

  • fever or chills
  • increased production of mucus, change in the color of the mucus
  • increased coughing or difficulty breathing.

Other side effects

Common(may affect up to 1 in 10 people)

  • mouth thrush, white patches (spots) in the mouth or throat caused by a fungal infection (candidiasis). Rinsing your mouth with water immediately after using Trelegy Ellipta may help prevent this side effect
  • nose, sinus, or throat infection
  • upper respiratory tract infection
  • itching, runny nose, or blocked nose
  • pain in the back of the mouth and throat
  • sinus inflammation
  • inflammation of the lungs (bronchitis)
  • flu
  • common cold
  • headache
  • coughing
  • painful or frequent urination (may be signs of a urinary tract infection)
  • joint pain
  • back pain
  • constipation.

Uncommon(may affect up to 1 in 100 people)

  • irregular heartbeat
  • faster heartbeat
  • hoarseness
  • weakening of the bones which may cause fractures.
  • dry mouth
  • altered taste
  • blurred vision
  • increased eye pressure
  • eye pain.

Rare(may affect up to 1 in 1,000 people)

  • allergic reactions (see above in Section 4)
  • difficulty urinating (urinary retention)
  • pain or discomfort while urinating (dysuria)
  • awareness of heartbeats (palpitations)
  • anxiety
  • shakiness
  • muscle spasms
  • high blood sugar levels (hyperglycemia).

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storing Trelegy Ellipta

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.

Do not store above 30°C.

Keep the inhaler in the sealed tray to protect it from moisture and only remove it from the tray immediately before first use. Once the tray is opened, the inhaler can be used for 6 weeks. Write the date that you open the tray on the inhaler label in the space provided. The date should be written as soon as the inhaler is removed from the tray.

If stored in a refrigerator, allow the inhaler to reach room temperature for at least one hour before use.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and additional information

Trelegy Ellipta composition

The active substances are fluticasone furoate, umeclidinium bromide, and vilanterol.

Each inhalation provides a delivered dose (dose that comes out of the mouthpiece) of 92 micrograms of fluticasone furoate, 65 micrograms of umeclidinium bromide equivalent to 55 micrograms of umeclidinium, and 22 micrograms of vilanterol (as trifenatate).

The other ingredients are lactose monohydrate (see section 2 “Trelegy Ellipta contains lactose”) and magnesium stearate.

Appearance of the product and pack contents

Trelegy Ellipta is a powder for inhalation (single-dose).

The Ellipta inhaler is made up of a light grey plastic body, a beige mouthpiece cover, and a dose counter. It is packaged in a foil laminate strip pack with a peelable foil lid. The pack contains a desiccant to reduce moisture in the pack.

The active substance is presented as a white powder in separate blister strips inside the inhaler. Trelegy Ellipta is available in packs of 1 inhaler containing 14 or 30 doses (for a 14 or 30-day treatment) and in clinical packs containing 90 doses (3 inhalers of 30 doses, for a 90-day treatment). Not all pack sizes may be marketed.

Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk

Citywest Business Campus

Dublin 24

Ireland

Manufacturer

Glaxo Wellcome Production

Zone Industrielle No.2

23 Rue Lavoisier

27000 Evreux

France

You can request more information about this medicinal product from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Tel: + 32 (0) 10 85 52 00

Lietuva

UAB “BERLIN-CHEMIE MENARINI BALTIC”

Tel: + 370 52 691 947

[email protected]

Text in Bulgarian language including company name “Berlin-Chemie/A Menarini Bulgaria” Eood, phone number and email address

Luxembourg/Luxemburg

GlaxoSmithKline Pharmaceuticals s.a./n.v.

Belgique/Belgien

Tél/Tel: + 32 (0) 10 85 52 00

Ceská republika

GlaxoSmithKline s.r.o.

Tel: + 420 222 001 111

[email protected]

Magyarország

Berlin-Chemie/A. Menarini Kft.

Tel.: + 36 23501301

[email protected]

Danmark

GlaxoSmithKline Pharma A/S

Tlf: + 45 36 35 91 00

[email protected]

Malta

GlaxoSmithKline Trading Services Limited

Tel: + 356 80065004

Deutschland

GlaxoSmithKline GmbH & Co. KG

Tel.: + 49 (0)89 36044 8701

[email protected]

Nederland

GlaxoSmithKline BV

Tel: + 31 (0)33 2081100

[email protected]

Eesti

OÜ Berlin-Chemie Menarini Eesti

Tel: + 372 667 5001

[email protected]

Norge

GlaxoSmithKline AS

Tlf: + 47 22 70 20 00

Ελλάδα

Menarini Hellas A.E.

Τηλ: + 30 210 83161 11-13

Österreich

GlaxoSmithKline Pharma GmbH

Tel: + 43 (0)1 97075 0

[email protected]

España

GlaxoSmithKline, S.A.

Tel: + 34 900 202 700

[email protected]

Polska

GSK Services Sp. z o.o.

Tel.: + 48 (0)22 576 9000

France

Laboratoire GlaxoSmithKline

Tél: + 33 (0)1 39 17 84 44

[email protected]

Hrvatska

Berlin-Chemie Menarini Hrvatska d.o.o.

Tel: + 385 1 4821 361

[email protected]

Portugal

GlaxoSmithKline – Produtos Farmacêuticos, Lda. Tel: + 351 21 412 95 00

[email protected]

România

GlaxoSmithKline Trading Services Limited

Tel: + 40 800672524

Ireland

GlaxoSmithKline (Ireland) Limited

Tel: + 353 (0)1 4955000

Slovenija

Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o.

Tel: + 386 (0)1 300 2160

[email protected]

Ísland

Vistor hf.

Sími: + 354 535 7000

Slovenská republika

Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o.

Tel: + 421 2 544 30 730

[email protected]

Italia

GlaxoSmithKline S.p.A.

Tel: + 39 (0)45 7741 111

Suomi/Finland

GlaxoSmithKline Oy

Puh/Tel: + 358 (0)10 30 30 30

Κύπρος

GlaxoSmithKline Trading Services Limited

Τηλ: + 357 80070017

Sverige

GlaxoSmithKline AB

Tel: + 46 (0)8 638 93 00

[email protected]

Latvija

SIA Berlin-Chemie/Menarini Baltic

Tel: + 371 67103210

[email protected]

United Kingdom (Northern Ireland)

GlaxoSmithKline Trading Services Limited

Tel: + 44 (0)800 221441

[email protected]

Date of last revision of this prospectus:

Other sources of information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.

Step-by-step instructions for use

What is the inhaler?

The first time you use Trelegy Ellipta, you do not need to make sure the inhaler is working correctly, as it contains pre-measured doses and is ready to use directly.

Open box, inhaler, leaflet, desiccant, tray with compartments and tray lid shown individuallyYour Trelegy Ellipta inhaler pack contains:

The inhaler is packaged in a tray. Do not open the tray until you are ready to inhale a dose of the medicine. When you are ready to use the inhaler, remove the lid to open the tray. The tray contains a desiccant, to reduce moisture. Dispose of the desiccant bag, do notopen, ingest, or inhale it.

Hand removing blister pack from packaging and arrow indicating disposal of the same along with desiccant bag in trash can

When you take the inhaler out of its tray, it will be in the “closed” position. Do not open the inhaler until you are ready to inhale a dose of the medicine. You should write the “Discard by” date on the space provided on the inhaler label and on the pack. The “Discard by” date is 6 weeks from the date of opening the tray. After this date, the inhaler must not be used anymore.The tray can be discarded once it is opened.

If stored in a refrigerator, let the inhaler reach room temperature for at least 1 hour before use.

The step-by-step instructions for using the inhaler provided below can be used for both the 30-dose Ellipta inhaler (30-day treatment) and the 14-dose Ellipta inhaler (14-day treatment).

  1. Read the following instructions before using the inhaler

If the inhaler lid is opened and closed without inhaling the medicine, the dose will be lost.The lost dose will be retained safely inside the inhaler, but it will not be available for inhalation.

It is not possible to accidentally administer an extra dose or a double dose through one inhalation.

Inhaler device with lid and dose counter showing number 30, arrows indicating parts and operation

For the 14-dose inhaler, the dose counter will also show half in red when there are less than 10 doses left and then will show half in red with the number 0 after the last dose used. The dose counter will appear completely red if the lid is opened again.

  1. Prepare a dose

When you are ready to inhale a dose, open the inhaler lid.

Do not shake the inhaler.

  • Slide the lid down until you hear a ‘click’.

Intrauterine device with cup-shaped appearance showing lines and curved arrow indicating deployment movementWhite plastic mouthpiece with conical shape and rounded tip for nasal applicationLong, narrow ventilation slot with curved edge and top text in black lettersText “Click” in bold black letters on a white background with subtle shading

Now, the medicine is ready to be inhaled.

As confirmation, the dose counter decreases by 1unit.

  • If the dose counter does not decrease when you hear the ‘click’, the inhaler will not release the dose of the medicine.Take it to the pharmacist and ask for help.
  • Do not shake the inhaler at any time.
  1. Inhale the medicine
  • While keeping the inhaler away from your mouth, breathe out as much as you can.

Do notbreathe out into the inhaler.

  • Place the mouthpiece between your lips and close them firmly around the mouthpiece.

Female face profile inhaling with grey and white oral inhaler and explanatory textDo notblock the ventilation slots with your fingers.

  • Take a long, steady, and deep breath in. Hold your breath for as long as you can (at least 3-4 seconds).
  • Take the inhaler out of your mouth.
  • Breathe out slowly and gently.

You may not be able to taste or feel the medicine, even when using the inhaler correctly.

Beforeclosing the lid, the inhaler mouthpiece may be cleaned using a dry tissue.

  1. Close the inhaler and rinse your mouth
  • Slide the lid up, to the top, to cover the mouthpiece.

Auto-injector device with partially removed protective cover showing numerical window 29 and arrow indicating direction

  • Rinse your mouth with water after using the inhaler, do not swallow.

This will make it less likely that you will get side effects such as mouth or throat ulcers.

Online doctors for TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose)

Discuss questions about TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose), including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (17)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.

Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate
Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.

She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.

With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose)?
TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose) requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose)?
The active ingredient in TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose) is vilanterol, umeclidinium bromide and fluticasone furoate. This information helps identify medicines with the same composition but different brand names.
How much does TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose) cost in pharmacies?
The average pharmacy price for TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose) is around 75.87 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose)?
TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose) is manufactured by Glaxosmithkline Trading Services Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose) online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose) is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose)?
Other medicines with the same active substance (vilanterol, umeclidinium bromide and fluticasone furoate) include ELEBRATO ELLIPTA 92/55/22 micrograms inhalation powder (single dose), ANORO ELLIPTA 55 MCG/22 MCG INHALATION POWDER (SINGLE-DOSE), BRIMICA GENUAIR 340/12 micrograms powder for inhalation. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media